Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer
- PMID: 21062933
- DOI: 10.1158/1078-0432.CCR-10-1371
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer
Abstract
Purpose: In epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy for lung cancer patients, acquired resistance develops almost inevitably and this limits the improvement in patient outcomes. EGFR T790M mutation and MET amplification are the two main mechanisms underlying this resistance, but the relationship between these two mechanisms is unclear. In this study, we explored their relationship using in vitro models and autopsy specimens.
Experimental design: Erlotinib-resistant HCC827 (HCC827ER) cells were developed by chronic exposure to erlotinib at increasing concentrations. HCC827EPR cells were also developed by chronic exposure to erlotinib in the presence of PHA-665,752 (a MET TKI). The erlotinib-resistant mechanisms of these cells were analyzed. In addition, 33 autopsy tumor samples from 6 lung adenocarcinoma patients harboring multiple gefitinib-refractory tumors were analyzed.
Results: HCC827ER developed MET amplification, and clinically relevant resistance occurred at ≥4-fold MET gene copy number gain (CNG). By contrast, HCC827EPR developed T790M without MET CNG. Of six patients harboring gefitinib-refractory tumors, three exhibited T790M only, one exhibited MET amplification only, and the other two exhibited T790M and/or MET amplification depending on the lesion sites. In these gefitinib-refractory tumors, T790M developed in 93% (14 of 15) of tumors without MET gene CNGs, in 80% (4 of 5) of tumors with moderate MET gene CNGs (<4-fold), and in only 8% (1 of 13) of tumors with MET amplification (≥4-fold).
Conclusions: These results indicate a reciprocal and complementary relationship between T790M and MET amplification and the necessity of concurrent inhibition of both for further improving patient outcomes.
©2010 AACR.
Similar articles
-
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25. Mol Cancer Ther. 2012. PMID: 22844075
-
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.Oncogene. 2009 Aug;28 Suppl 1(Suppl 1):S24-31. doi: 10.1038/onc.2009.198. Oncogene. 2009. PMID: 19680293 Free PMC article. Review.
-
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. Clin Lung Cancer. 2009. PMID: 19632948 Free PMC article. Review.
-
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.Pathol Oncol Res. 2009 Dec;15(4):651-8. doi: 10.1007/s12253-009-9167-8. Epub 2009 Apr 21. Pathol Oncol Res. 2009. PMID: 19381876
-
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7. doi: 10.1073/pnas.0710370104. Epub 2007 Dec 18. Proc Natl Acad Sci U S A. 2007. PMID: 18093943 Free PMC article.
Cited by
-
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.Target Oncol. 2023 May;18(3):425-440. doi: 10.1007/s11523-023-00955-9. Epub 2023 Apr 5. Target Oncol. 2023. PMID: 37017806 Free PMC article.
-
Efficacy of PP121 in primary and metastatic non‑small cell lung cancers.Biomed Rep. 2023 Mar 1;18(4):29. doi: 10.3892/br.2023.1611. eCollection 2023 Apr. Biomed Rep. 2023. PMID: 36926188 Free PMC article.
-
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.Cancers (Basel). 2023 Jan 11;15(2):460. doi: 10.3390/cancers15020460. Cancers (Basel). 2023. PMID: 36672409 Free PMC article.
-
New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.Curr Treat Options Oncol. 2022 Nov;23(11):1626-1644. doi: 10.1007/s11864-022-01022-7. Epub 2022 Oct 15. Curr Treat Options Oncol. 2022. PMID: 36242712 Review.
-
IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells.Sci Signal. 2022 Aug 16;15(747):eabj5879. doi: 10.1126/scisignal.abj5879. Epub 2022 Aug 16. Sci Signal. 2022. PMID: 35973030 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous